Federal grant · project grant (b)
Sequencing the Mono-methylated Derivatives of Cytidine - Project Summary the Goal of This Project Is to Develop a Prototype Sequencing Platform and the Associated Methodology Capable of Directly Sequencing the Mono-methylated Derivatives of Cytosine. Recently, Lc-ms/ms Methods to Assess the Presence of the Mono-methylated Isomers of Cytosine, I.e., 5-METHYLCYTOSINE (M5C), 4-METHYLCYTIDINE (M4C), 3- Methylcytidine (M3C), 2`-O-METHYLCYTIDINE (CM), as Well as the Bismethyl Derivative 5-METHYL-2`-O-METHYLCYTIDINE (M5CM), Have Made Promising Discoveries That These Modifications Change When Cells Are Exposed to Oxidative and Inflammatory Stress, Micronutrient Stress, and Heat Shock Stress. Moreover, the Placement and Extent of Methylated Cytosine Rna Nucleotides Is Now Believed to Be Important in Neurodevelopment, Appears to Impact Intelligence, and Changes With Cancer, Eczema, and Metabolic Disorders. However, No Technology Currently Exists That Is Capable of Sequencing and Quantifying These Chemical Marks, Severely Limiting the Field’s Understanding and Potential Utilization of These Modifications as Biomarkers (for Diagnostics, Prognostics, and Therapeutic Purposes, as Examples). in Order to Enable the Proposed Feat, During This Project, We Will Specifically Be Developing a Novel Nanopore-based Reader With the Sensitivity to Directly Differentiate the Mono-methylated Isomers of Cytosine as Well as the Associated Sequencing Platform for Semi-automated, Stable, High-accuracy Sequencing Measurements. We Will Then Demonstrate and Optimize the Developed Sequencing Methodology Through Various Sequencing Demonstrations, Including Sequencing and Mapping the Mono-methylated Derivates of Cytosine Across Rna From Two Different Cell Lines. Upon the Completion of This Project, We Will Have Developed, Optimized, and Fully Demonstrated the World’s First Functioning Prototype Sequencer Capable of Directly Sequencing the Mono-methylated Derivatives of Cytosine.
Committed
$400,000
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.